Chemotherapy
Lurbinectedin + Doxorubicin for Leiomyosarcoma
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new drug, lurbinectedin, combined with an existing chemotherapy drug, doxorubicin, in patients with advanced leiomyosarcoma. The goal is to see if this combination is safe and more effective than doxorubicin alone. Both drugs work by damaging the DNA in cancer cells, leading to their death. Lurbinectedin is a synthetic marine-derived anticancer agent that has shown promise in treating certain types of cancer.
Alkylating agents
Surgery + HIPEC with Chemotherapy for Uterine Cancer
Recruiting1 awardPhase 2
Stanford, California
This trial uses heated chemotherapy in the abdomen to treat patients with recurring uterine cancer. The heat helps the drug work better, and additional medication is given to target any remaining cancer cells.
Popular Filters
Trials for LMS Patients
Virus Therapy
Tabelecleucel for EBV Associated Diseases
Recruiting1 awardPhase 2
Orange, California
This trial tests tabelecleucel, a treatment using special immune cells, in patients with certain diseases related to the Epstein-Barr virus (EBV) who can't use or don't respond to standard treatments. It works by enhancing the immune system's ability to attack virus-infected cells. Tabelecleucel is being tested for recurring or hard-to-treat EBV-related diseases.
Checkpoint Inhibitor
Pre-Surgery Nivolumab + BO-112 for Soft Tissue Sarcoma
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing the side effects of a combination of two drugs, one of which helps the body's immune system attack cancer cells, before surgery in patients with a type of cancer that can be removed surgically.
Trials for Uterine Leiomyosarcoma Patients
Virus Therapy
Tabelecleucel for EBV Associated Diseases
Recruiting1 awardPhase 2
Orange, California
This trial tests tabelecleucel, a treatment using special immune cells, in patients with certain diseases related to the Epstein-Barr virus (EBV) who can't use or don't respond to standard treatments. It works by enhancing the immune system's ability to attack virus-infected cells. Tabelecleucel is being tested for recurring or hard-to-treat EBV-related diseases.
Checkpoint Inhibitor
Pre-Surgery Nivolumab + BO-112 for Soft Tissue Sarcoma
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing the side effects of a combination of two drugs, one of which helps the body's immune system attack cancer cells, before surgery in patients with a type of cancer that can be removed surgically.
Trials for Metastatic Patients
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Phase 3 Trials
Alkylating agents
Chemotherapy + Radiation for Soft Tissue Sarcoma
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Trials With No Placebo
Virus Therapy
Tabelecleucel for EBV Associated Diseases
Recruiting1 awardPhase 2
Orange, California
This trial tests tabelecleucel, a treatment using special immune cells, in patients with certain diseases related to the Epstein-Barr virus (EBV) who can't use or don't respond to standard treatments. It works by enhancing the immune system's ability to attack virus-infected cells. Tabelecleucel is being tested for recurring or hard-to-treat EBV-related diseases.
Checkpoint Inhibitor
Pre-Surgery Nivolumab + BO-112 for Soft Tissue Sarcoma
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing the side effects of a combination of two drugs, one of which helps the body's immune system attack cancer cells, before surgery in patients with a type of cancer that can be removed surgically.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.